Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.53 |
| ▸ | PARP1 | P09874 | 10/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 6/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | DRD2 | P14416 | 4/20 | 0.39 |
| ▸ | DRD4 | P21917 | 4/20 | 0.39 |
| ▸ | DRD3 | P35462 | 4/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30040691 | 1.00 | RPS6KB1 (0.53) | RPS6KB1PARP1PARP2KCNH2DRD2 | |
| SCHEMBL30041365 | 0.87 | RPS6KB1 (0.55) | RPS6KB1PARP1DRD2DRD4DRD3 | |
| SCHEMBL23964270 | 0.86 | RPS6KB1 (0.51) | RPS6KB1PARP1PARP2KCNH2DRD2 | |
| SCHEMBL30041144 | 0.83 | RPS6KB1 (0.49) | RPS6KB1PARP1PARP2KCNH2DRD2 | |
| SCHEMBL23964160 | 0.83 | RPS6KB1 (0.49) | RPS6KB1PARP1PARP2KCNH2DRD2 | |
| SCHEMBL23932576 | 0.83 | RPS6KB1 (0.47) | RPS6KB1PARP1PARP2KCNH2DRD2 | |
| SCHEMBL30041918 | 0.83 | RPS6KB1 (0.47) | RPS6KB1PARP1PARP2KCNH2DRD2 | |
| SCHEMBL30042040 | 0.81 | HRH4 (0.58) | HRH4 | |
| SCHEMBL25505907 | 0.81 | HRH4 (0.58) | HRH4 | |
| SCHEMBL23964268 | 0.76 | RPS6KB1 (0.42) | RPS6KB1PARP1PARP2KCNH2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150980-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2023-05-18 | — | — | US | disclosed |
| CN-115427404-A | Collagen 1 translation inhibitors and methods of use thereof | 艾尼莫生物科技公司 | 2022-12-02 | — | — | CN | disclosed |
| WO-2021216665-A9 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2021-12-02 | — | — | WO | disclosed |
| WO-2021216665-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150980-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | COL1A1, COL2A1, COL14A1 | RPS6KB1 316/4885PARP1 193/4885PARP2 1629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.